CompletedNCT01689389
Quetiapine Extended-Release Use in Routine Care in France
About this title
Read the official source — NCT01689389Observational studyAges 18–130FranceSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 130 years.
- Listed locations
- Argenteuil and 18 more locationsSee all locations and recruitment
Study information
Study start dateDecember 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 2,292
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- France
- Age range
- From 18 Years to 130 Years
- Official registry ID
- NCT01689389
- Official title
Show the full official title
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Argenteuil · Belley · Castelmaurou
16 more locations
- Cavaillon
- Les Mureaux
- Lille
- Marseille
- Montpellier
- Nîmes
- Obernai
- Paris
- Rennes
- Saint-Dizier
- Saint-Égrève
- Saintes
- Sens
- Toulouse
- Tours
- Ussel
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Who was this study for?
Listed age limits: 18 years to 130 years.
